Domov › Skvamóznocelulárny karcinóm hlavy a krku › Oklahoma › Oklahoma City
Klinické štúdie Skvamóznocelulárny karcinóm hlavy a krku v meste Oklahoma City, OK
13 štúdií pre Skvamóznocelulárny karcinóm hlavy a krku hľadá účastníkov v zariadeniach v meste Oklahoma City a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Prebieha náborFáza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Prebieha náborFáza 3
- University of Oklahoma Health Sciences Center, Oklahoma City
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Prebieha náborFáza 3
- Stephenson Cancer Center, Oklahoma City
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Prebieha náborFáza 1
- Normunity Investigational Site, Oklahoma City
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Prebieha náborFáza 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Prebieha náborFáza 1/2
- SSM OKC Hightower Clinical, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Prebieha náborFáza 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Prebieha náborFáza 1
- Dren Investigational Site, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Prebieha náborFáza 1
- University of Oklahoma, Oklahoma City
Štúdie Skvamóznocelulárny karcinóm hlavy a krku v iných mestách
- Houston, TX47 štúdií
- Los Angeles, CA42 štúdií
- Boston, MA40 štúdií
- New York City, NY39 štúdií
- Nashville, TN39 štúdií
- St. Louis, MO28 štúdií
- Arlington, VA26 štúdií
- Philadelphia, PA26 štúdií
- Chicago, IL26 štúdií
- Atlanta, GA24 štúdií
- San Antonio, TX22 štúdií
- New Haven, CT22 štúdií
Iné štúdie v Oklahoma City
- Nemalobunkový karcinóm pľúc28 štúdií
- Rakovina vaječníkov28 štúdií
- Rakovina endometria25 štúdií
- Kolorektálny karcinóm22 štúdií
- Rakovina prostaty21 štúdií
- Rakovina pľúc19 štúdií
- Rakovina prsníka17 štúdií
- Metastatická rakovina16 štúdií
- Rakovina (všetky typy)14 štúdií
- Akútna myeloidná leukémia14 štúdií
- Rakovina močového mechúra11 štúdií
- Rakovina pankreasu11 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.